Versatile Dosage Options: Available in 100,000 IU for elderly and 200,000 IU for adults and adolescents
Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance
Science Translational Medicine, 10(467), eaar7047
Larazotide is currently being studied for illnesses of intestinal permeability and is the subject of a late-phase clinical trial for patients with celiac disease, whose intestinal barrier is compromised
ZR2024QH068) and the Research Fund for Lin Hes Academician Workstation for New Medicine and Clinical Translation at Jining Medical University (No